Long-term safety and effi cacy of rituximab in 7 japanese patients with anca-associated vasculitis

Modern Rheumatology

Volumn 25, Issue 4, 2015, Pages 603-608

  Nagafuchi, Hiroko ^a   Atsumi, Tatsuya ^b   Hatta, Kazuhiro ^c   Muso, Eri ^d   Takeno, Mitsuhiro ^e   Yamada, Hidehiro ^a   Ozaki, Shoichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c TENRI HOSPITAL   (Japan)

^d Kitano Hospital   (Japan)

^e YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ANCA associated vacuities; Efficacy; Rituximab; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ADRAFINIL; AZATHIOPRINE; C REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; HEPARIN; LIVER ENZYME; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; IMMUNOLOGIC FACTOR; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; AIRWAY OBSTRUCTION; ANCA ASSOCIATED VASCULITIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DEATH; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; JAPAN; LIVER CELL CARCINOMA; LONG TERM CARE; LOW DRUG DOSE; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; MULTICENTER STUDY; NOSE SEPTUM PERFORATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE RISK; RECURRENT INFECTION; REMISSION; SEPSIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; TREATMENT DURATION; URINARY TRACT INFECTION; VISUAL DISORDER; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CONTROLLED STUDY; DOSE RESPONSE; IMMUNOLOGY; INCIDENCE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; REMISSION INDUCTION; RITUXIMAB; TREATMENT OUTCOME;

EID: 84934901366     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.981945     Document Type: Article

References (37)

1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92.
2. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005; 52(8):2461–9.
3. Rutgers A, Kallenberg CG. Refractory vasculitis. Autoimmun Rev. 2011;10(11):702–6.
4. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al.; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.
5. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’ s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9(5):842–52.
6. Kosits C, Callaghan M. Rituximab: a new monoclonal antibody therapy for non-Hodgkin’s lymphoma. Oncol Nurs Forum. 2000;27(1):51–9.
7. Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol. 2012;8(9):505–14.
8. Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, et al. Rituximab in severe lupus nephritis: early B-cell depletion aff ects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4(3):579–87.
9. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–81.
10. Shin JI, Eisenhut M. A beneficial effect of rituximab on autoimmune thrombotic thrombocytopenic purpura: just a B-cell depletion? J Allergy Clin Immunol. 2014;133(2):600.
11. Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52–7.
12. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.
13. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.
14. Lovric S, Erdbruegger U, Kümpers P, Woywodt A, Koenecke C, Wedemeyer H, et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant. 2009;24(1):179–85.
15. Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’ s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327–33.
16. Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther. 2013; 15(5):R133.
17. Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, et al.; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013;65(9):2441–9.
18. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modifi cation and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–32.
19. Information for Healthcare Professionals: Rituximab (marketed as Rituxan) FDA ALERT [12/2006] http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm126519.htm Accessed on 24th January 2007.
20. Nakabayashi K, Hashimoto H. Microscopic polyangiitis. In: Hashimoto H, (ed.). Clinical Manual for Vasculitis (in Japanese). Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan; 2002. pp. 24–6.
21. Yoshida M. Wegener’s granulomatosis. In: Hashimoto H, (ed.). Clinical Manual for Vasculitis (in Japanese). Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan; 2002. pp. 30-4.
22. Tsusaka N. Allergic granulomatous angiitis. In: Hashimoto H, (ed.). Clinical Manual for Vasculitis (in Japanese). Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan; 2002. pp. 27-9.
23. Ballow M. Primary immunodefi ciency disorders: antibody defi ciency. J Allergy Clin Immunol. 2002;109(4):581-91.
24. Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford). 2014;53(3):532-9.
25. Specks U. Biologic agents in the treatment of granulomatosis with polyangiitis. Cleve Clin J Med. 2012;79(Suppl 3):S50-3.
26. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B-cells are required for generation of protective eff ector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006;176(10):6147-54.
27. Besada E, Nossent JC. Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis? Clin Rheumatol. 2013;32(11):1677-81.
28. Mahr A, Heijl C, Le Guenno G, Faurschou M. ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol. 2013;27(1):45-56.
29. Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology. 2004; 43(12):1532-5.
30. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener’ s granulomatosis. Int J Cancer. 2002;100(1):82-5.
31. van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann R, Furst DE, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558-67.
32. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908.
33. Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, et al. Decreased CD5 + B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013;8(3):382-91.
34. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, Grasland A, Zoulim A, LE Guen J, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012;39(1):125-30.
35. Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology. 2013;52(11):2041-7.
36. De Lind van Wijngaarden RA, van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JW, et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol. 2008;3(1):237-52.
37. Kobayashi S. Epidemiology about the ANCA-related vasculitis (in Japanese). Rheumatica. 2008;40(1):1–7.